Preparation of chitosan-plasmid DNA nanoparticles encoding interleukin-12 and their expression in CT-26 colon carcinoma cells

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 14, Issue 2, 2011, Pages 181-195

  Hallaj Nezhadi, Somayeh ^a,b   Valizadeh, Hadi ^a   Dastmalchi, Siavoush ^a,b   Baradaran, Behzad ^a   Jalali, Mohammad Barzegar ^a   Dobakhti, Faramarz ^c   Lotfipoure, Farzaneh ^d  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CHITOSAN; INTERLEUKIN 12; NANOCARRIER; PLASMID DNA;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; COACERVATION; COLON CARCINOMA; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENETIC TRANSFECTION; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

EID: 79959299267     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3tp4t     Document Type: Article

References (52)

1. Curiel, D T.; Douglas JT., Cancer Gene Therapy. Humana Press Inc, Totowa, NJ, 2005.
2. Cortesina G, De Stefani A, Sacchi M, Rosso S, Galeazzi E. Immunomodulation therapy for squamous cell carcinoma of the head and neck. Head Neck, 1993; 15:266-70.
3. Kresina TF. An Introduction to Molecular Medicine and Gene Therapy. A JOHN WILEY & SONS, INC, New York, 2001.
4. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med, 1993; 178:1223-30.
5. Ma X, Trinchieri G. Regulation of interleukin-12 production in antigen-presenting cells. Adv Immunol, 2001; 79:55-92.
6. Skeen MJ, Miller MA, Shinnick TM, Ziegler HK. Regulation of murine macrophage IL-12 production. Activation of macrophages in vivo, restimulation in vitro, and modulation by other cytokines. J Immunol, 1996; 15:1196-206.
7. Fallarino F, Uyttenhove C, Boon T, Gajewski TF. Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. J Immunol, 1996; 156:1095- 100.
8. Rodolfo M, Colombo MP. Interleukin-12 as an adjuvant for cancer immunotherapy. Methods, 1999; 1:114-20.
9. Noguchi Y, Richards EC, Chen YT, Old LJ. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc Natl Acad Sci U S A, 1995; 92:2219-23.
10. Colombo MP, Trinchieri G. Interleukin-12 in antitumor immunity and immunotherapy. Cytokine Growth Factor Rev, 2002; 13:155-68.
11. Albini A, Brigati C, Ventura A, Lorusso G, Pinter M, Morini M, et al. Angiostatin anti-angiogenesis requires IL-12: the innate immune system as a key target. J Transl Med, 2009; 7:5.
12. Siddiqui F, Ehrhart EJ, Charles B, Chubb L, Li CY, Zhang X, et al. Anti-angiogenic effects of interleukin-12 delivered by a novel hyperthermia induced gene construct. Int J Hyperthermia, 2006; 22:587-606.
13. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst, 1995; 8:581-6.
14. Car BD, Eng VM, Lipman JM, Anderson TD. The toxicology of interleukin-12: a review. Toxicol Pathol, 1999; 27:58-63.
15. Yockman JW, Maheshwari A, Han SO, Kim SW. Tumor regression by repeated intratumoral delivery of water soluble lipopolymers/p2CMVmIL-12 complexes. J Control Release, 2003; 87:177-86.
16. Tan J, Newton CA, Djeu JY, Gutsch DE, Chang AE, Yang NS, et al. Injection of complementary DNA encoding interleukin-12 inhibits tumor establishment at a distant site in a murine renal carcinoma model. Cancer Res, 1996; 56:3399-403.
17. Davis ME. Non-viral gene delivery systems. Curr Opin Biotechnol, 2002; 13:128-31.
18. Schmidt-Wolf GD, Schmidt-Wolf IG. Non-viral and hybrid vectors in human gene therapy: an update. Trends Mol Med, 2003; 9:67-72.
19. Alonso MJ. Nanomedicines for overcoming biological barriers. Biomed Pharmacother, 2004; 58:168-72.
20. Basarkar A, Singh J. Nanoparticulate systems for polynucleotide delivery. Int J Nanomedicine, 2007; 2:353-60.
21. Huang, L.; Hung MCH.; Wagner, E., Non-viral Vectors for Gene Therapy. Elsevier Inc, California, USA, 2005.
22. Guang Liu W, De Yao K. Chitosan and its derivatives--a promising non-viral vector for gene transfection. J Control Release, 2002; 83:1-11.
23. Dass CR, Choong PF. Chitosan-mediated orally delivered nucleic acids: a gutful of gene therapy. J Drug Target, 2008;16:257-61.
24. Tan ML, Choong PF, Dass CR. Cancer, chitosan nanoparticles and catalytic nucleic acids. J Pharm Pharmacol, 2009; 61:3-12.
25. Baldrick P. The safety of chitosan as a pharmaceutical excipient. Regul Toxicol Pharmacol. Apr;56(3):290-9.
26. Lai WF, Lin MC. Nucleic acid delivery with chitosan and its derivatives. J Control Release, 2009; 134:158-68.
27. Borchard G. Chitosans for gene delivery. Adv Drug Deliv Rev, 2001; 52:145-50.
28. Patil SD, Rhodes DG, Burgess DJ. DNA-based therapeutics and DNA delivery systems: a comprehensive review. AAPS J, 2005; 7:E61-77.
29. Zitvogel L, Tahara H, Cai Q, Storkus WJ, Muller G, Wolf SF, et al. Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. Hum Gene Ther, 1994; 5:1493-506.
30. Meko JB, Yim JH, Tsung K, Norton JA. High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12. Cancer Res, 1995; 55:4765-70.
31. Chen L, Chen D, Block E, O'Donnell M, Kufe DW, Clinton SK. Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer. J Immunol, 1997; 159:351-9.
32. Faneca H, Cabrita AS, Simoes S, Pedroso de Lima MC. Evaluation of the antitumoral effect mediated by IL-12 and HSV-tk genes when delivered by a novel lipid-based system. Biochim Biophys Acta, 2007; 1768:1093-102.
33. Speroni L, Gasparri J, de los ABV, Chiaramoni NS, Smagur A, Szala S, et al. Antitumoral effect of IL 12 gene transfected via liposomes into B16F0 cells. Acta Biochim Pol, 2009; 56:249-53.
34. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol, 2008; 26:5896-903.
35. Maheshwari A, Mahato RI, McGregor J, Han S, Samlowski WE, Park JS, et al. Soluble biodegradable polymer-based cytokine gene delivery for cancer treatment. Mol Ther, 2000; 2:121-30.
36. Fewell JG, Matar M, Slobodkin G, Han SO, Rice J, Hovanes B, et al. Synthesis and application of a nonviral gene delivery system for immunogene therapy of cancer. J Control Release, 2005; 109:288-98.
37. Wang Y, Gao S, Ye WH, Yoon HS, Yang YY. Codelivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat Mater, 2006; 5:791-6.
38. Diez S, Migueliz I, Tros de Ilarduya C. Targeted cationic poly(D,L-lactic-co-glycolic acid) nanoparticles for gene delivery to cultured cells. Cell Mol Biol Lett, 2009; 14:347-62.
39. Chew JL, Wolfowicz CB, Mao HQ, Leong KW, Chua KY. Chitosan nanoparticles containing plasmid DNA encoding house dust mite allergen, Der p 1 for oral vaccination in mice. Vaccine, 2003; 21:2720-9.
40. Gao Y, Zhang Z, Chen L, Gu W, Li Y. Chitosan Nbetainates/ DNA self-assembly nanoparticles for gene delivery: in vitro uptake and transfection efficiency. Int J Pharm, 2009; 371:156-62.
41. Corsi K, Chellat F, Yahia L, Fernandes JC. Mesenchymal stem cells, MG63 and HEK293 transfection using chitosan-DNA nanoparticles. Biomaterials, 2003; 24:1255-64.
42. Mao HQ, Roy K, Troung-Le VL, Janes KA, Lin KY, Wang Y, et al. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Control Release, 2001; 70:399-421.
43. Sato T, Ishii T, Okahata Y. In vitro gene delivery mediated by chitosan. effect of pH, serum, and molecular mass of chitosan on the transfection efficiency. Biomaterials, 2001; 22:2075-80.
44. Lee CH, Ni YH, Chen CC, Chou C, Chang FH. Synergistic effect of polyethylenimine and cationic liposomes in nucleic acid delivery to human cancer cells. Biochim Biophys Acta, 2003; 1611:55-62.
45. Ishii T, Okahata Y, Sato T. Mechanism of cell transfection with plasmid/chitosan complexes. Biochim Biophys Acta, 2001; 1514:51-64.
46. Ozgel G, Akbuga J. In vitro characterization and transfection of IL-2 gene complexes. Int J Pharm. 2006; 315:44-51.
47. Han S, Mahato RI, Sung YK, Kim SW. Development of biomaterials for gene therapy. Mol Ther, 2000; 2:302-17.
48. Anwer K, Rhee BG, Mendiratta SK. Recent progress in polymeric gene delivery systems. Crit Rev Ther Drug Carrier Syst, 2003; 20:249-93.
49. Li XW, Lee DK, Chan AS, Alpar HO. Sustained expression in mammalian cells with DNA complexed with chitosan nanoparticles. Biochim Biophys Acta, 2003; 1630:7-18.
50. Fischer D, Li Y, Ahlemeyer B, Krieglstein J, Kissel T. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials, 2003; 24:1121-31.
51. Lavertu M, Methot S, Tran-Khanh N, Buschmann MD. High efficiency gene transfer using chitosan/DNA nanoparticles with specific combinations of molecular weight and degree of deacetylation. Biomaterials, 2006; 27:4815-24.
52. Bowman K, Leong KW. Chitosan nanoparticles for oral drug and gene delivery. Int J Nanomedicine, 2006; 1:117-28.